Harilalith Kovvuri

[S Nagendra Boopathy @BoopathyCardio]

Single catheter strategy for STEMI- PPCI may become the norm . Our initial experience is reported here . @PLOSONE
@SRIHER_Official @SRMC_official @cardiosadha2 #STEMI #PPCI #Timesavedismusclesaved

https://t.co/wYOkCYvKiy

[Davide Capodanno @DFCapodanno]

A shift from ticagrelor to prasugrel occurred in Denmark following the findings of the ISAR-REACT 5 trial and the updated ESC guideline recommendation favoring prasugrel. In 2019, more than 99% of patients received ticagrelor; by 2022, 89% received prasugrel.

This study is truly exceptional in its scope: among 10,984 patients with myocardial infarction undergoing PCI, prasugrel was associated with lower rates of MACE and recurrent myocardial infarction after statistical adjustment, with similar bleeding rates compared with ticagrelor. These results were replicated in a propensity score–matched cohort, in patients aged ≥75 years, and in those with non-STEMI.

Considering the TUXEDO-2 data presented at #AHA25 and soon to be published, and with the inevitable meta-analysis that will strengthen the case for prasugrel, this nationwide study adds further evidence that the two "more potent P2Y12 inhibitors" are, after all, not as equivalent as often assumed.

https://t.co/FgTWmXl4zD

[S Nagendra Boopathy @BoopathyCardio]

Calcified CAD Management .
https://t.co/UpPrdSC2tI
@MountSinaiHeart @ccclivecases @SRIHER_Official @SRMC_official @drvenkat2517 @aiims_newdelhi

[Shikha Jha M.D.🫀 @Shikha_Cardio]

TCT 2025 LATE BREAKING CLINICAL TRIALS: One LINER SUMMARY 📸 AT A GLANCE ⭐️ What a phenomenal scientific meeting! Congratulations to all the presenters & leaders for their innovation, hard work and knowledge sharing. Thank you @TCTConference @TCTMD @crfheart team for a fantastic meeting! #TCT2025 #FIT 🫀❤️ 😊

[S Nagendra Boopathy @BoopathyCardio]

Happy to share our work on OPN in ISR : ICI based study .
Link s below
https://t.co/gnBlRJOswI
@SRMC_official @SRIHER_Official @Translumina_in @CuculiFlor3264 @cardiosadha2 @RameshSank1975 @sis_medical

[Muthu Vaduganathan @mvaduganathan]

🔥 New in @NatureMedicine

How do you communicate lifetime benefits expected with HFpEF therapies?

New data from 3 RCTs (#DELIVER #FINEARTS #PARAGON) estimate up to *5 years* of event-free survival w combination Rx

#GDMT for HFpEF has finally arrived!

🔗https://t.co/ozSx3UwkLN

[Harilalith Kovvuri @harilalith]

@Apple Make a ‘Water consumption widget’ and integrate into activity rings, to track daily water intake. An essential for working individuals. #applewatch #Activityrings #hydrate #Stayhealthy

[Shikha Jha M.D.🫀 @Shikha_Cardio]

#ESC2025 Late Breaking Clinical Trials ⭐️
One LINER SUMMARY: At a glance 📸🫀
Outstanding amount of research♥️
Trailblazing scientific advances 🙌
#ESCCongress #WCCardio
@JACCJournals @ACCinTouch @NEJM @TheLancet @JAMA_current @CardioNerds

[S Nagendra Boopathy @BoopathyCardio]

CHIP mutations in Indian CAD patients . Presented at ESC,2025. @ICMRDELHI @SRIHER_Official @SRMC_official #ESCCongress @escardio

[S Nagendra Boopathy @BoopathyCardio]

The FINEARTS-HF study's underreporting of significant hyperkalaemia risk, a potentially serious adverse effect associated with mortality in heart failure patients, rises concerns about a potential "post-RALES" effect. In addition, The PARADIGM-HF study demonstrated that a “U” shaped relation between dyskalaemia and mortality.The present study did not categorize hypokalaemia into distinct severity levels to understand the degree of hypokalaemia. Also, absence of mineralocorticoid receptor blocker in the control arm might be thepotential cause of  higher hypokalaemia. A more detailed analysis of dyskalaemia severity and their relationship with clinical outcomes is warranted. In spite of clear evidence having a higher mortality following heart failure hospitalization than unplanned urgent visits, the authors did not report them separately leading a potential reporting bias. Given Finerenone's increased risk of hyperkalaemia, particularly severe cases requiring hospitalization (Table.1), and its lack of Cardiovascular mortality benefit and unreported reduction in heart failure hospitalizations, a more cautious interpretation of the study is warranted !
@NEJM #FINEARTS-HF @DrRajeevagarwa3 @drkarthik2010 @DrGJustinPaul1 @drjohnm @TCTMD @ESC_Journals @harilalith

[K. Creek @sgrstk]

Birds literally just eat, travel, and shit on things they don't like. I don't know about you, but that's the lifestyle I'm striving for.

[K. Creek @sgrstk]

Have you met the one? First, ask yourself, "Can I live without them?" If "No," ask yourself if you're drunk—because you're being ridiculous.

[Branden Moskwa @bmoskwa]

A #Startup is a #Company that is confused about What its #Product is, Who its #Customers are, How to Make Money. - @davemcclure

[Harilalith Kovvuri @harilalith]

@PMOIndia https://t.co/G8VlpGmtZ5